Detalles de la búsqueda
1.
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Kidney Int
; 100(1): 225-237, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33307104
2.
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Blood
; 133(6): 540-549, 2019 02 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30510079
3.
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Haematologica
; 106(1): 230-237, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31949012
4.
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Eur J Haematol
; 106(3): 389-397, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33301613
5.
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Pediatr Nephrol
; 36(4): 889-898, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33048203
6.
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Kidney Int
; 97(6): 1287-1296, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32299680
7.
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Br J Haematol
; 191(3): 476-485, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32449174
8.
Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237.
Kidney Int
; 104(1): 205, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37349053
9.
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Kidney Int
; 99(5): 1244, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33892867
10.
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Pediatr Nephrol
; 36(4): 1033, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33296010
11.
Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.
Kidney Int
; 98(6): 1621, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33276869
12.
A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.
Am J Ther
; 22(5): e130-40, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25853236
13.
Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Front Neurol
; 15: 1332890, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38356884
14.
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
J Neurol
; 270(6): 3129-3137, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36890354
15.
Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Adv Ther
; 40(1): 211-232, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36272026
16.
Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹4C]-aclidinium bromide in healthy subjects.
Biopharm Drug Dispos
; 33(1): 39-45, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22275272
17.
Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series.
Am J Reprod Immunol
; 88(2): e13559, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35514201
18.
Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019.
Infect Dis Ther
; 10(2): 1045-1054, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826106
19.
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Trials
; 21(1): 639, 2020 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32660611
20.
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.
Ther Adv Hematol
; 11: 2040620720966137, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33178408